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Betaxolol (Bx) is a member of β-blockers, a
group of drugs frequently used in therapy of cardiac
arrhythmias, arterial hypertension, angina pectoris,
myocardial infarction and related conditions. The car-
dioselective β1-blocker betaxolol (1-{4[2-(cyclo-
propylmethoxy)ethyl]phenoxy}-3-(propan-2-
ylamino)propan-2-ol) also has membrane-stabilizing
action on myocardial muscle fibrils. Some of these
drugs have been misused by athletes or horses partici-
pating in highly competitive events to decrease mus-
cular convultions and palpitations. Bx as preparation
for eye is currently used for treatment of glaucoma due
to its high efficiency in intra-ocular pressure decreas-
ing effect (1). Topically administered Bx enters the
eye through local absorption, and it may reach con-
centrations in the pharmacologically active range
within many anterior and posterior segment tissues.
Bx is a highly lipophilic compound (experi-
mental log P = 2.4), freely soluble in water, soluble
in ethanol and methylene chloride (2, 3). 
A large number of reports have been published
about the determination of Bx. Spectrophotometric
methods have been applied for the determination of
Bx in pharmaceutical preparations and in bulk drug
(4-6). The screening analyses of multiple β-blockers
in a single run have been mostly achieved by HPLC
[7-11]. Bx and 15 other β-blockers presenting a
wide range of lipophilicity have been determined in
urine samples by GC/MS and LC/MS to compare
the limits for doping tests [12]. HPLC with fluores-
cence detection has been applied for the determina-
tion of Bx in human aqueous humor [13]. Residues
of Bx and 18 other β-blockers have been determined
in animal tissues by HPLC coupled with tandem
mass spectrometry [14]. Bx in ophthalmic solutions
has also been determined by TLC-densitometric and
videodensitometric method [15]. In our previous
publications, we have investigated the influence of
basic and acidic environment on the degradation
process of atenolol, acebutolol and propranolol and
the correlation between stability described by kinet-
ic parameters and polarity of drugs [16, 17]. To the
authorsí knowledge no papers concerning degrada-
tion studies of Bx under different conditions with
the establishing of degradation pathway are avail-
able in the literature. 
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Abstract: The purpose of this work was to develop a sensitive stability indicating TLC-densitometric method
for the determination of betaxolol (Bx) in pharmaceutical preparations and to study the stability of Bx in acidic
solutions. The method was developed on TLC aluminium plates precoated with silica gel F254 using the mobile
phase chloroform-methanol-ammonia 25% (18 : 4 : 0.2, v/v/v) which gives compact spots for Bx (Rf ≅ 0.64)
and its degradation product (Rf ≅ 0.39). Densitometric analysis was carried out in UV at 280 nm. The devel-
oped method is highly sensitive (LOD = 66.6 ng/spot, LOQ = 200 ng/spot), precise (RSD = 2.73%) and accu-
rate (mean recovery = 100.28% at 100% level). Bx was subjected to acidic and alkaline hydrolysis but degra-
dation was observed only in acidic solutions. The degradation process was described with kinetic and thermo-
dynamic parameters. Based on LC-ESI/MS analysis, it was found that Bx decomposes in acidic solution to pro-
duce ethoxyphenoxy-3-[(1-methylethyl)amino]propan-2-ol.
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The aim of this work was the development and
validation of a TLC-densitometric method for the
determination of Bx in pharmaceutical preparations
and in the presence of its degradation product.
Additionally, Bx was forcibly degraded in acidic
environment and the developed method was used to
detect and quantitatively estimate the degradation
product generated. The degradation product of Bx
was subjected to LC-ESI/MS analysis to establish its
chemical structure. Bx degradation process and
identification of degradation product described in
this work were not a subject of studies of any other
authors. 
EXPERIMENTAL
Equipment
Densitometer TLC Scanner 3 with Cats 4 soft-
ware (Camag, Switzerland); sample applicator
Linomat V (Camag, Switzerland); Silica gel alu-
minium TLC F254 plates No. 1.05554 (Merck,
Darmstadt, Germany); TLC glass chamber of 18 × 8
× 15 cm in size (Sigma-Aldrich, St. Louis, USA);
Incubator ECOCELL55-BMT (Brno, Czech
Republic); Mass spectrometer API 2000 (Applied
Biosystems MDX SCIEX, Concorde, Ontario,
Canada); HPLC system with Xterra column Waters)
and DAD detector (Agilent Technologies,
Waldbronn, Germany).
Reagents and chemicals
Standard substance: betaxolol (1-{4[2-(cyclo-
propylomethoxy)ethyl]phenoxy}-3-(propan-2-
ylamino)propan-2-ol) hydrochloride (LGC
Standards, USP106990-3). Reagents: methanol,
chloroform, formic acid, acetonitrile and water
(Merck, Darmstadt, Germany), sodium hydroxide,
ammonia and hydrochloric acid (POCh Gliwice,
Poland). 
Preparations used for analysis 
The following preparations were analyzed:
Lokren ñ tablets cont. 20 mg of betaxolol
hydrochloride s. AR95HR (Sanofi Aventis,
RzeszÛw, Poland); Lokren - tablets cont. 20 mg of
betaxolol hydrochloride s. 23001 (Synthelabo
groupe, Tours, France); Optibetol 0.5% - eye drops
cont. 5 mg/mL of betaxolol s. 01Y00108
(Warszawskie Zak≥ady Farmaceutyczne Polfa,
Warszawa, Poland). 
Solutions
Standard solutions were prepared by dissolving
appropriate amount of betaxolol standard substance
in methanol to give a concentration of 0.01% (w/v).
Sample solutions of Lokren were prepared by grind-
ing 10 tablets in a mortar, weighing the amount of
tablet powder corresponding to 25 mg of Bx and
shaking with 50 mL of methanol for 30 min. Then,
the solution was placed in ultrasonic bath for 30
min, after that it was filtered and diluted with
methanol at the ratio of 1 : 5, v/v. 
Sample solutions of Optibetol were prepared
by dilution of 1 mL of preparation solution with
methanol at the ratio of 1 : 50, v/v. 
TLC conditions
The conditions for the analysis of Bx were
established by experimental selection of the appro-
priate stationary phase and mobile phase enabling
the separation of active substance and its possible
degradation products. Standard solutions in the
amount of 20 µL were applied in the form of 10 mm
bands, 10 mm apart, 10 mm from the lower edge of
the plate to chromatographic plates TLC silica gel
60 with F254 fluorescence agent (Merck, Darmstad,
Germany) 10 × 10 cm in size using sample applica-
tor Linomat V equipped with 100 µL syringe. A
constant application rate of 200 nL/s was used.
Chromatograms were developed over a distance of
95 mm using chloroform-methanol-ammonia 25%
(18 : 4 : 0.2, v/v/v) mobile phase in chromatograph-
ic chamber saturated for 15 min with mobile phase
vapor at room temperature. Each chromatogram was
developed separately and every time a freshly pre-
pared mobile phase was used. After development,
the TLC plates were dried at room temperature and
analyzed densitometrically in UV at λ = 280 nm,
that was chosen as the analytical wavelength on the
basis of absorption spectra of Bx recorded directly
from chromatogram. Densitometric scanning was
carried out using a CAMAG TLC Scanner 3,
equipped with deuterium lamp, controlled by CATS
4 Software resident in the system. The slit dimen-
sions were 8 × 0.6 mm, the scanning speed 20 mm/s
and data resolution 100 µm/step. Retardation factors
Rs were used for the identification of Bx and possi-
ble degradation products.
Validation of the method
The developed method was validated by the
determination of specificity, accuracy, precision,
inter-day precision, linearity, limit of detection and
quantitation according to ICH guidelines [18]. 
The specificity of the method was ascertained
by analysis of standard solution and drug samples.
The spots were identified by comparison of the Rf
values and spectra of Bx with those obtained for the
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standard. For extracted solution used for determina-
tion purposes, no additional spots were found and no
visible interferences from excipients were observed. 
The linearity was expressed as a relationship
between peak area and analyte concentration within
a specified measuring range. To determine linearity,
a series of five solutions (three bands per concentra-
tion) at a concentration ranging from 0.2 µg/spot to
2.5 µg/spot for Bx were prepared. The regression
plot, its regression equation and the correlation coef-
ficient r = 0.9949 are indicative of linearity.
Limits of detection (LOD) and quantitation
(LOQ) were determined on the basis of the standard
deviation and slope of the straight line obtained
from the equations: LOD = 3.3◊Se/a, LOQ =
10◊Se/a, where: Se ñ the standard error of the esti-
mate, a ñ the slope of a straight line.
The accuracy of the method was defined as %
recovery of Bx added at three levels 80, 100 and 120%
into a sample containing a known amount of Bx. 
Precision of the method was carried out using
six replicates of a sample solutions on the same day
(intra-day precision). The degree of consistency of
the results obtained for the analyte samples was
checked by different analyst who made the analysis
in one week interval (inter-day precision). The pre-
cision was estimated using peak areas and was eval-
uated as the standard deviation (SD) and relative
standard deviation (RSD) values. 
To examine robustness, the most significant
chromatographic parameters were changed within
the range 1-5% compared to those of the optimal
conditions, while keeping the other parameters
unchanged. The following parameters were
changed: volume of chloroform, volume of
methanol. The influence of stationary phase
was also checked by application of silica gel
aluminium HPTLC F254 plates (Merck,
Germany; #1.05548.0001) instead of silica gel
aluminium TLC F254 plates.
As a result of validation process analysis con-
ditions were established, which were used for the
determination of Bx.
TLC analysis of betaxolol in drugs
Solutions of Bx (20 µL of standard solution
and 20 µL of sample solutions for determination of
active substance) were applied with an applicator to
the plates of 10 × 10 cm in size (cut from 20 × 20 cm
plates before use). Chromatograms were developed
to a distance of 95 mm with chloroform-methanol-
ammonia 25% (18 : 4 : 0.2, v/v/v) as a mobile phase.
Densitometric measurements were carried out by
scanning chromatograms at λ = 280 nm. The con-
centration of betaxolol in tested preparations was
computed by comparing the peak areas for standard
and sample solutions. 
Stability studies of betaxolol in acidic solutions
The influence of pH, temperature and incuba-
tion time on stability of Bx in solutions was investi-
gated using newly developed and validated method
[19]. For this purpose samples were prepared by
mixing 2 mL of Bx stock solution 0.6% (w/v) with
2 mL of 2.00 M HCl, 1.00 M HCl and 0.50 M HCl
in glass ampoules and heated in an electronic incu-
bator up to the desired temperature. Temperature
selection and incubation time were set experimen-
tally. Incubation was performed at temperatures of
90, 100 and 110OC. The amount of 500 µL of incu-
bated solutions were taken for the analysis. After
cooling, the solutions were dissolved with methanol
at 1 : 1 ratio. The amount of 20 µL of the resultant
solutions were applied to the TLC plates in tripli-
cate. The chromatographic-densitometric analysis
was carried out according to the developed method.
For quantitative determination in degradation stud-
ies, the scan areas of appropriate peaks were record-
ed, and the percent concentrations of each con-
stituent were computed by employing the internal
normalization method, according to the formula: %I
= (xi/Sx) × 100 where %I is constituent concentra-
tion, xi is peak area for the determined constituent,
and Sx is sum of peak scan areas in the chro-
matogram. 
Analysis of degradation product
The obtained hydrolizates after incubation at
100OC were subjected to LC-ESI/MS analysis.
Identification of studied drug and its degradation
product was done from mass spectra obtained direct-
ly from chromatographic peaks in their appropriate
retention times using a validated high-performance
liquid chromatography tandem mass spectrometry
method in the positive ionization mode.
Liquid chromatography was performed using
an Agilent 1100 (Agilent Technologies, Waldbronn,
Germany) LC system consisting of degasser, a gra-
dient pump, an autosampler and a DAD detector.
Chromatographic separation was carried out with a
commercially available XBridge C18 column (30
mm ◊ 2.1 mm, 3.5 µm, Waters, Ireland) set at 30OC.
A sample volume of 20 µL was injected onto an ana-
lytical column. The mobile phase consisting of ace-
tonitrile and water with an addition of 0.01% formic
acid was set at a flow rate of 0.6 mL/min using a
gradient elution 0ñ5 min water, 5ñ7 min acetonitrile,
7ñ20 min water. 
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Mass spectrometric detection was performed on
an Applied Biosystems MDS Sciex (Concord,
Ontario, Canada) API 2000 triple quadrupole mass
spectrometer equipped with an electrospray ionization
(ESI) interface, performed in the positive ion mode. 
A standard solution of polypropylene glycols
was used for instrument tuning and mass calibration
at unit mass resolution according to the Applied
Biosystems manual. The mass spectrometer was
operated with a dwell time of 200 ms, and a 5 ms
delay between scans for each transition on the first
quadrupole (Q1) in a range from 50 to 600 amu.
The mass spectrometric conditions were opti-
mized by continuously infusing the standard solu-
tion of Bx using a Harvard infusion pump set at 10
µL/min. Parameters of ion source were: ion spray
voltage 5500 V, gas 1 ñ 20 psi, gas 2 ñ 25 psi, ion
source temperature 550OC, curtain gas ñ 6 psi.
Parameters of ion path were: declustering potential
61 V, focusing potential 360 V, entrance potential
12 V and electron multiplier 2300 V. 
Data acquisition and processing were accom-
plished using the Applied Biosystems Analyst ver-
sion 1.4.2 software. 
Table 1. Summary of validation results for the determination of Bx
Parameter Result  
RF 0.64  
Linearity [µg/spot]
0.2 ñ 2.5
P = a c + b
a = 84.087; b = 352.5
r = 0.9949
LOD [ng/spot] 66.6  
LOQ [ng/spot] 200  
Accuracy [%] Level 80%: xmean = 98.27
n = 6 SD = 0.84, RSD = 0.85%
Level 100%: xmean = 100.28
SD = 1.36, RSD = 1.36%
Level 120%: xmean = 98.95
SD = 1.20, RSD = 1.21%
Intra-day precision xmean = 2110.9
n = 6 SD = 48.43, RSD = 2.29%
µ = 2110.9 ± 124.51
Inter-day precision xmean = 2116.7
n = 6 SD = 27.31, RSD = 1.29%
µ = 2116.7 ± 70.21
P - peak area; c - concentration; r - correlation coefficient; SD - standard deviation; m - 95% confidence inter-
val; RSD - relative standard deviation (%).
Table 2. The results of Bx determination in pharmaceutical preparations with statistical analysis. 
Preparation Declared content Determined content 
Statistical analysis
(n = 6)  
Optibetol 0.5% 5 mg/mL 4.69 4.85 xm = 4.8083
4.75 4.91 SD = 0.0776
4.82 4.83 RSD = 1.61%
Lokren 20 mg/tablet 18.51 18.85 xm = 18.8200
Sanofi Aventis 18.20 18.74 SD = 0.4400
19.31 19.31 RSD = 2.34%
Lokren 20 mg/tablet 19.57 18.72 xm = 18.7783
Synthelabo group 18.34 18.95 SD = 0.4789
18.85 18.24 RSD = 2.55%
xm - arithmetic mean, SD - standard deviation, RSD - relative standard deviation (%).
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RESULTS AND DISCUSSION
According to the aim of this paper a new chro-
matographic-densitometric method has been devel-
oped for the determination of Bx in pharmaceutical
preparations and for stability studies of Bx in acidic
environment. By using TLC F254 silica gel coated
plates as a stationary phase and chloroform-
methanol-ammonia 25% (18 : 4 : 0.2, v/v/v) as the
mobile phase chosen experimentally after testing
several different mobile phases, dense, compact and
well shaped bands of Bx were obtained (Fig. 1). No
significant changes in the Rf of Bx were observed
when the composition of the mobile phase was
slightly changed. Densitometric analysis was carried
out at λ = 280 nm, that was chosen as the analytical
wavelength on the basis of absorption spectra of Bx
recorded directly from chromatogram (Fig. 2). The
Figure 1. Densitogram registered for Bx standard solution
Figure 2. Absorption spectrum obtained from Bx standard solution registered directly from chromatogram
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Figure 3. Densitogram of Bx (2) and its degradation product (1) after incubation for 3 h in 0.5 M HCl at 100OC
Figure 4. Chromatogram of control sample of Bx (A), mass spectrum of control sample of Bx at retention time of 3.02 min (B)
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Figure 5. Chromatogram of Bx sample in acidic conditions (A), mass spectrum of studied sample of Bx at retention time of 3.09 min (B)
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developed method was proven to have high sensitiv-
ity, wide linearity range, good accuracy and preci-
sion by the validation results (Table 1). 
The determination results of Bx in available
pharmaceutical preparations obtained by the devel-
oped method do not differ from those declared by
manufacturers (Table 2). 
The influence of pH, temperature and incuba-
tion time on stability of Bx in solutions was investi-
gated using newly developed and validated method.
Temperature selection and incubation time were set
experimentally. Incubation was performed at tem-
peratures of 90, 100 and 110OC for acidic solutions
(Table 3). The densitogram presented in Figure 3
shows besides Bx (Rf = 0.64) additional well
resolved peak representing degradation product (Rf
= 0.39) appearing in acidic environment. The rela-
tionship between Bx concentration and time, log(c)
= f(t) showed that degradation of Bx follows the
kinetics of first order reaction. To obtain full char-
acteristics of degradation process, kinetic parame-
ters (the reaction rate constants k, half-life t0.5 and
the time t0.1 in which the concentration of betaxolol
is reduced by 10%) and thermodynamic parameters
were calculated [20]. The fastest degradation of Bx
was observed in acidic solution (1 M HCl) at 110OC
k = 0.78 h-1 and the lowest degradation of Bx was in
acidic solution (0.25 M HCl) at 90OC k = 0.012 h-1.
The results presenting kinetic evaluation of degrada-
tion studies of Bx are shown in Table 4. 
The obtained degradation product was subject-
ed to HPLC/ESI-MS analysis in order to identify its
molecular weight. Figure 4A illustrates the HPLC
diode array UV-VIS chromatogram of control sam-
ple of Bx obtained under the analytical conditions.
In the HPLC/DAD chromatogram Bx was observed
at retention time of 3.02 min. Figure 4B illustrates
the full scan mass spectrum of control sample of Bx
obtained under the LC-ESI/MS conditions. Based
on mass spectra of Bx standard solution we could
find out the parent drug and the occurrence of poten-
tial degradative products of Bx. For precursor ion
Figure 6. The plausible degradation pattern of Bx in acidic conditions
Table 3. Results from Bx stability studies in acidic environment.
Bx mean concentration [%] n = 3
HCl
[mol/L] 
Time [h] 90OC 100OC 110OC  
0 100 100 100   
1 100 92.15 93.14
0.25
2 98.59 91.44 80.08
3 96.23 88.30 60.90    
0 100 100 100   
1 95.86 84.60 86.70  
0.50
2 90.95 80.22 61.69   
3 84.72 75.09 42.38    
0 100 100 100   
1 83.44 69.80 69.25  
1.00
2 73.84 58.84 31.53   
3 67.94 51.61 9.69 
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molecular mass, m/z 308 amu eluted at retention
time of 3.02 min. was observed. 
Figure 5A shows the HPLC diode array UV-
VIS chromatogram of Bx after degradation in acidic
solution at 100OC. In the chromatogram there are
two main peaks observed at retention time of 3.09
and 2.41 min. Figure 5B confirms the existence of
the parent drug with molecular mass m/z 308 amu.
Moreover, in Figure 5C at retention time of 2.41 min
we could observe the elution of the fragment with
molecular mass m/z 253.9 amu, probably due to the
loss of cyclopropylmethyl moiety from parent struc-
ture. The intensity of main degradation product in
acidic conditions was very high. The analysis of
chemical structure of the main degradation product
revealed that Bx decomposes to ethoxyphenoxy-3-
[(1-methylethyl)amino]propan-2-ol. The LC-
ESI/MS analysis enabled to create the plausible
degradation pattern of Bx under mentioned condi-
tions that is presented in Figure 6. 
CONCLUSIONS
The developed method may be applied for the
determination of Bx in pharmaceutical preparations
and for stability studies of Bx by quantitative deter-
mination of Bx in the presence of its degradation
product. It was found that degradation of Bx
depends on the acidic environment but in basic solu-
tions Bx is very stable. Calculated kinetic and ther-
modynamic parameters describe the degradation
process of Bx and HPLC/ESI-MS analysis enabled
to establish chemical structure of the main degrada-
tion product. 
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